A study, led by researchers at the Johns Hopkins Kimmel Cancer Center, that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.
Anna Berkenblit, a clinical oncologist and drug developer, was named the first-ever chief scientific and medical officer of the Pancreatic Cancer Action Network.
